Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — H1 2022 Earnings Presentation
17 slides from Elixinol Wellness's earnings presentation, Aug 30, 2022
Slide 1: H1 FY22 Results Presentation
ASX:EXL H1 FY22 Results Presentation August 2022 1
Slide 2: Disclaimer
Disclaimer This presentation contains summary information about Elixinol Wellness Limited (Elixinol Wellness) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with Elixinol Wellness’ other periodic and c
Slide 3: Table of Contents
Table of Contents • Vision & Purpose • Financial Highlights • Operational Highlights • H1 FY22 Results Summary • Segment Performance • Financial Summary • Cash Flow • Financial Position • Strategy & Outlook • Global Consumer Trends & Market Outlook • Global Strategy & Initiatives • New Product Devel
Slide 4: To create a healthier everyday life through the power of hemp and plant-based products
Hemp Foods Australia (foods, supplements & skincare) Vision To create a healthier everyday life through the power of hemp and plant-based products Ambition Building a global, natural wellness consumer products company Purpose Changing lives naturally! Elixinol Americas (digestible & topical products
Slide 5: Financial Highlights
Financial Highlights Elixinol Wellness reports ongoing improvements in Adjusted EBITDA and continues to be well capitalised with a strong funding position. 30% cost base reduction Operational and corporate cost reduction initiatives have significantly reduced operating expenses in H1 FY22 compared w
Slide 6: Operational Highlights
Operational Large scale business transformation drives a further $3.0m (30%) OPEX Investment focus on AU and US markets with strongest competitive position simplifies Highlights savings with additional optimisation initiatives implemented. our business model and enables group to compete more effecti
Slide 7: H1 FY22 Results Summary
H1 FY22 Results Summary 7
Slide 8: Segment Performance
Segment Performance Driving EBITDA improvement across all business units. A$’m Australia Americas Rest of World Corporate H1 FY22 H1 FY21 H1 FY22 H1 FY21 H1 FY22 H1 FY21 H1 FY22 H1 FY21 Revenue 1.7 1.9 1.5 2.6 - 0.3 Gross profit 0.5 0.6 0.9 1.8 - 0.1 GP% 31% 31% 63% 72% - 24% Operating expenses (1.0
Slide 9: Financial Summary
Financial Summary Focus on branded products, e-commerce and tight cost controls drives significant profit improvement. A$’m H1 FY22 H1 FY21 Revenue 3.2 4.8 Cost of goods sold (1.7) (2.3) Gross profit 1.5 2.5 GP% 47% 52% Operating expenses (7.0) (10.0) Non-operating (expenses)/income 0.1 0.4 • Strate
Slide 10: Cash Flow
Cash Flow • Simplified operating model has driven significant cost savings: 34% reduction in cash used in operations. • 34% reduction in cash used operating activities vs H1 FY21 • 14% reduction in operating cash outflows vs H2 FY21 • Based on Q2 FY22, approximately 5 quarters of funding (including
Slide 11: Financial Position
Financial Position Well funded with $6.9m cash and virtually no debt. A$’m 30 June 2022 31 December 2021 Current assets Cash and cash equivalents 6.9 12.6 Trade & other receivables 2.5 3.0 Inventories 2.2 2.2 Other 1.2 1.8 Total current assets 12.8 19.6 Non-current assets Property, plant and equipme
Slide 12: Strategy & Outlook
Strategy & Outlook 12
Slide 13: Outlook: Hemp food and CBD products an answer to the growing trend for plant-based nutrition
Outlook: Hemp food and CBD products an answer to the growing trend for plant-based nutrition and nutraceuticals Hemp food in Australia CBD in U.S.A. The rise in dietary trends such as vegan / vegetarian and flexitarian has seen Sales are expected to reach $12.0 billion by 2026, driven by consumers t
Slide 14: Global Strategy & Initiatives
Global Strategy & Initiatives VISION: To create a healthier everyday life through the power of hemp & plant-based products REGIONAL PRIORITIES: As we re-build profitability, we will focus our investments on our most established markets in the US and Australia where we have a strong competitive posit
Slide 15: New Product Development
New Product Development Investment in building a R&D and innovation capability has delivered a wide reaching new product launch pipeline that will see new product throughout FY22. LAUNCHED H2 FY22 • Adaptogen capsule • Sleep liposomes • Extra strength gummies Elixinol will expand offering with new •
Slide 16: Summary
Well positioned in global consumer wellness trend for natural and plant-based food and nutraceuticals Business transformation Improved outlook to a leaner cost structure, further due to a better economic strengthening fundamentals environment and end of COVID-19 restrictions Summary New product deve
Slide 17: Thank you
—_— -Organic- Wholefood Plant Protein Thank you Seeger 06006 — Creamy & Delicious — @ ElixinolWellness Natural wellness for people and the planet